Powered by Guardant Infinity smart liquid biopsy platform, advanced multiomic test evaluates genomic, epigenomic and RNA-based molecular data First tissue comprehensive genomic profiling test to offer ...
While the advancement of comprehensive genomic profiling (CGP) ushers in a more targeted approach to treating patients with cancer, BillionToOne says its approach could overcome limitations present in ...
A lung cancer diagnosis is often described through familiar terms such as the stage, size and location of a tumour. But there is another layer of information that can be equally important when doctors ...
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that it has received new commercial health plan coverage for the ...
--Landmark approval advances personalized cancer care as an estimated 1 in 3 patients across five common advanced cancers are expected to match with an FDA-approved therapy-- CAMBRIDGE, ...
Characterization of Non–Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns Among 31,165 (97.2%) samples where ...
Oncotarget published "Analytic validation and clinical utilization of the comprehensive genomic profiling test, GEM ExTra®" which reported that the authors developed and analytically validated a ...
Please provide your email address to receive an email when new articles are posted on . A lipid profiling blood test may predict the risk for type 2 diabetes and CVD years in advance, according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results